TY - JOUR
T1 - Role of agents other than tumor necrosis factor blockers in the treatment of psoriatic arthritis
AU - Atzeni, Fabiola
AU - Costa, Luisa
AU - Caso, Francesco
AU - Scarpa, Raffaele
AU - Sarzi-Puttini, Piercarlo
PY - 2015/11/1
Y1 - 2015/11/1
N2 - Psoriatic arthritis (PsA) is a systemic inflammatory disease characterized by possible peripheral and axial joint involvement, enthesitis, dactylitis, and skin and nail disease. It affects up to one-third of psoriatic patients, and may be associated with comorbidities such as cardiovascular and metabolic diseases. The usually prescribed initial treatment of moderate-severe PsA is methotrexate, which may be accompanied or replaced by a tumor necrosis factor (TNF) inhibitor such as etanercept, infliximab, or adalimumab. However, some patients may become unresponsive (or have contraindications) to available anti-TNF agents and require alternative treatment. The aim of this review is to describe the potential role of some new immunomodulatory agents. The Journal of Rheumatology
AB - Psoriatic arthritis (PsA) is a systemic inflammatory disease characterized by possible peripheral and axial joint involvement, enthesitis, dactylitis, and skin and nail disease. It affects up to one-third of psoriatic patients, and may be associated with comorbidities such as cardiovascular and metabolic diseases. The usually prescribed initial treatment of moderate-severe PsA is methotrexate, which may be accompanied or replaced by a tumor necrosis factor (TNF) inhibitor such as etanercept, infliximab, or adalimumab. However, some patients may become unresponsive (or have contraindications) to available anti-TNF agents and require alternative treatment. The aim of this review is to describe the potential role of some new immunomodulatory agents. The Journal of Rheumatology
KW - Apremilast
KW - Interleukin-17 inhibitors
KW - Psoriatic arthritis
KW - Rituximab
KW - Tumor necrosis factor inhibitors
KW - Ustekinumab
UR - http://www.scopus.com/inward/record.url?scp=84951790429&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84951790429&partnerID=8YFLogxK
U2 - 10.3899/jrheum.150643
DO - 10.3899/jrheum.150643
M3 - Article
C2 - 26523064
AN - SCOPUS:84951790429
VL - 93
SP - 79
EP - 81
JO - Journal of Rheumatology
JF - Journal of Rheumatology
SN - 0315-162X
ER -